Study of Attention and Memory Treatments for Cancer Survivors
30 maart 2022 bijgewerkt door: University of California, San Francisco
A Pilot Study of A Novel Cognitive Intervention for Cancer Survivors
This clinical trial investigates if certain electronic games may be effective in improving attention and memory function in cancer survivors.
Cancer related cognitive impairment (CRCI) is an issue experienced by many cancer patients/survivors.
CRCI includes perceived or objective problems with memory, executive function, and attention/concentration. CRCI has a negative impact on survivors' ability to work, carry out routine activities, and engage in social and family relationships.
CRCI may result in significant distress and reduced quality of life.
Certain electronic games may help improve attention and memory function in cancer survivors and reduce symptoms of CRCI.
Studie Overzicht
Toestand
Voltooid
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. Determine the recruitment and retention rates for both arms of this study. II. Determine the effect size for changes in cognitive function (i.e., Test of Variables of Attention (TOVA) [i.e. attention], Adaptive Cognitive Evaluation (ACE) [i.e. working memory]) in the intervention group compared to the control group following the 4-week study.
III. Evaluate adherence rates for and satisfaction with the interventions. IV. Evaluate for treatment-related adverse events (e.g., nausea, motion sickness).
SECONDARY OBJECTIVE:
I. To determine effect sizes for depression, fatigue, and sleep disturbance, by comparing changes in the intervention group to changes in the control group, following the 4-week study.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
ARM II: Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
Studietype
Ingrijpend
Inschrijving (Werkelijk)
49
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
California
-
San Francisco, California, Verenigde Staten, 94143
- University of California San Francisco
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Attention Function Index (AFI) score of < 7.5
- Are able to read, write, and understand English
- Ability to understand an electronic informed consent document, and the willingness to sign it
- Have a Karnofsky performance status (KPS) score of >= 50
- Have access to WiFi connection
Exclusion Criteria:
- Receiving active treatment for cancer recurrence
- Have significant cognitive impairment
- Have sensory or motor deficits that prevent them from doing the assessment and using the application
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm I (Endeavor)
Patients play Endeavor over 25 minutes daily 5 days a week for 4 weeks.
|
Endeavor application will be utilized by participant on iPad
Andere namen:
Standardized QOL questionnaire will be administered at each study visit
|
|
Actieve vergelijker: Arm II (Words!)
Patients play Words! over 25 minutes daily 5 days a week for 4 weeks.
|
Standardized QOL questionnaire will be administered at each study visit
Words! application will be utilized by participant on iPad
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Percentage of participants who completed the study
Tijdsspanne: Up to 6 weeks
|
Completion is defined as participants who completed all 4 weeks of intervention and final assessment.
|
Up to 6 weeks
|
|
Mean change in scores on the Test of Variables of Attention (TOVA) over time
Tijdsspanne: Up to 4 weeks
|
The TOVA records responses to visual or auditory stimuli through the participants iPAD, with a unique, highly accurate +/1 millisecond (ms) microswitch.
The TOVA (Copyright 1991- 2021 by The TOVA Company) automatically calculates response time variability (consistency), response time (speed), commissions (impulsivity), and omissions (focus and vigilance).
Results are reported as standard scores (average = 100 with a standard deviation of 15) and are compared to a large normative sample stratified by gender and age.
Scores above 85 are within normal limits, 80-85 are borderline, and below 80 are not within normal limits.
The mean change in scores will be estimated as the norm-based standardized difference in means from enrollment (Week 1) to the last assessment (Week 4).
|
Up to 4 weeks
|
|
Percent change in scores on the TOVA over time
Tijdsspanne: Up to 4 weeks
|
The TOVA records responses to visual or auditory stimuli through the participants iPAD, with a unique, highly accurate +/1 millisecond (ms) microswitch.
The TOVA (Copyright 1991- 2021 by The TOVA Company) automatically calculates response time variability (consistency), response time (speed), commissions (impulsivity), and omissions (focus and vigilance).
Results are reported as standard scores (average = 100 with a standard deviation of 15) and are compared to a large normative sample stratified by gender and age.
Scores above 85 are within normal limits, 80-85 are borderline, and below 80 are not within normal limits.
Will be estimated as the standardized difference between the groups in the percent score change from enrollment (Week 1) to the last assessment (Week 4).
|
Up to 4 weeks
|
|
Mean changes in Adaptive Cognitive Evaluation (ACE)
Tijdsspanne: Up to 4 weeks
|
The ACE is a mobile cognitive control assessment battery containing standard tests that assess different aspects of cognitive control (attention, working memory, and goal management), modified by incorporating adaptive algorithms, immersive graphics, video tutorials, motivating feedback, and a user-friendly interface.
The ACE is administered to all participants via iPad and the scores will be estimated as the standardized difference in means from enrollment (Week 1) to the last assessment (Week 4).
|
Up to 4 weeks
|
|
Percent change in scores on the ACE over time
Tijdsspanne: Up to 4 weeks
|
The ACE is a mobile cognitive control assessment battery containing standard tests that assess different aspects of cognitive control (attention, working memory, and goal management), modified by incorporating adaptive algorithms, immersive graphics, video tutorials, motivating feedback, and a user-friendly interface.
The ACE is administered to all participants via iPad and the scores will be estimated as the standardized difference between the groups in the percent score change from enrollment (Week 1) to the last assessment (Week 4).
|
Up to 4 weeks
|
|
Proportion of time using application
Tijdsspanne: Up to 4 weeks
|
Adherence rate will be evaluated by comparing the amount of time the participant should have used the application to the actual amount of time the participant used the application.
|
Up to 4 weeks
|
|
Percentage of participants who experienced treatment-related adverse events
Tijdsspanne: Up to 6 weeks
|
Safety analyses will involve examination of and comparison between groups for the percentage of participants by adverse event severity and type of treatment-related adverse events.
Comparisons of the frequencies between groups will be conducted using Chi-square or Fisher's exact test.
|
Up to 6 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in mean severity scores on the Center for Epidemiologic Studies - Depression Scale (CES-D)
Tijdsspanne: Up to 4 weeks
|
The CES-D scale is a brief self-report scale designed to measure self-reported symptoms associated with depression experienced in the past week.
Responses are rated on a 5 point Likert scale with response option ranging 0="Rarely or none of the time (less than 1 day )" to 4='Most or all of the time (5-7 days)".
The scoring of positive items is reversed.
Possible range of scores is 0 to 60, with the higher scores indicating the presence of more symptomatology and will be estimated as the standardized difference in means of each measure at the last assessment from enrollment to the last assessment.
|
Up to 4 weeks
|
|
Change in mean severity scores on the Lee Fatigue Scale
Tijdsspanne: Up to 4 weeks
|
The Lee Fatigue Scale is used to measure the impact of fatigue on a participants quality of life.
The scale consists of 18 items relating to the subjective experience of fatigue.
Each item is rated on a 0 to 10 numeric rating scale (e.g., from "not at all tired" to "extremely tired").
Scores can range from 0 to 10.
The instrument has two subscales: fatigue (items 1-5 and 11-18) and energy (items 6-10).
The fatigue subscale score is calculated as the mean of the 13 fatigue items and the energy subscale score is the mean of the 5 energy items.
Higher scores on the fatigue subscale represent greater fatigue severity, and higher scores on the energy subscale indicate higher levels of energy and will be estimated as the standardized difference in means of each measure at the last assessment from enrollment to the last assessment.
|
Up to 4 weeks
|
|
Change in severity scores on the General Sleep Disturbance Scale (GSDS)
Tijdsspanne: Up to 4 weeks
|
The GSDS consists of 21 items related to frequency in the past month of difficulty getting to sleep when respondents were asked to think about the past month, and each response is on a 8-point Likert scale from 0 ("never") to 7 ("all the time").
Will be estimated as the standardized difference in means of each measure at the last assessment, and as the difference between the groups in the percent change from enrollment to the last assessment.
|
Up to 4 weeks
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Christine Miaskowski, RN, PhD, University of California, San Francisco
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 maart 2021
Primaire voltooiing (Werkelijk)
31 januari 2022
Studie voltooiing (Werkelijk)
31 januari 2022
Studieregistratiedata
Eerst ingediend
28 april 2021
Eerst ingediend dat voldeed aan de QC-criteria
28 april 2021
Eerst geplaatst (Werkelijk)
3 mei 2021
Updates van studierecords
Laatste update geplaatst (Werkelijk)
8 april 2022
Laatste update ingediend die voldeed aan QC-criteria
30 maart 2022
Laatst geverifieerd
1 maart 2022
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 19803
- NCI-2021-02024 (Register-ID: CTRP (Clinical Trial Reporting Program))
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Nee
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
product vervaardigd in en geëxporteerd uit de V.S.
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .